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Abstract
Background: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic
lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could
eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic
body radiotherapy. This study aims to assess the impact of [18F]Choline ([18F]FMCH) PET/CT and the use stereotactic
body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa).
Methods: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [18F]FMCHPET/
CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous
metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [18F]FMCHPET/CT.
Results: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3–40
months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy,
and the median time of the primary endpoint was 39.7 months (CI 12.20–62.14 months). No grade 3 or 4 toxicity
was recorded.
Conclusions: Repeated salvage [18F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of
systemic therapy in selected patients with oligometastatic PCa.
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Background
Prostate cancer (PCa) is the most common malignant
tumour in men in Western countries. Considering the
progressive aging of the population, the clinical ap-
proach to this cancer needs to be redressed considering
the presence of comorbidities and on-going medical
treatments [1–3]. When the first-line curative strategies
fail and the PSA value increases, the critical issue in
asymptomatic PCa patients is the decision of whether to
initiate systemic therapy, including androgen deprivation
therapy (ADT) or chemotherapy [4, 5]. In recent years,
improvements and availability of functional imaging
modalities (e.g. radiolabeled choline PET/CT) have
increased the detection of active metastatic lesions, even
at low PSA level [6–8]. Therefore, by the increasing
availability of radiolabeled choline PET/CT, a new entity
of patients that present a limited number of active
metastatic lesions is having growing interest: the oligo-
metastatic patients [9–11]. Patients with oligometastatic
disease could eventually be managed by treating all the
active lesions with local therapy, i.e. either surgery or
ablative stereotactic body radiotherapy (SBRT) [12–16].
Evidence on the safety and response rate of SBRT for the
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treatment of metastatic disease is growing, including the
application in oligometastatic PCa [17, 18]. Despite the
clinical and radiological response rate being described in
more than 80 % of lesions treated with SBRT, target
lesions to be treated and the most suitable population
that would benefit from local treatment have yet to
be established [19, 20]. However, the impact of radi-
olabeled choline PET/CT in selecting patients and
validating the target lesions for subsequent SBRT has
yet to be investigated.
The main and final outcome of this prospective study is
the overall survival in patients with oligometastatic pros-
tate cancer treated with [18F] Fluoro-Methyl Choline
([18F]FMCH) PET/CT-guided SBRT. Surrogate endpoints
are the quality of life measured with EORTCT QLQ-C30,
toxicity and the time to subsequent treatment after PSA
recurrence detection [21]. The present manuscript reports
the preliminary of this study.
Methods
Study design and population
The study design is illustrated in Fig. 1.
Twenty-nine patients (median age of 71.2 years, range
50–79) with biochemical recurrence of prostate cancer
and oligometastatic disease, defined as up to three
synchronous (two or more lesions simultaneously re-
vealed by the same PET/CT) active metastatic lesions as
shown by [18F]FMCH uptake at PET/CT, were enrolled
in the study and were treated with SBRT (Table 1). The
study was approved by the local Institutional Review
Board. Patient characteristics are reported in Table 1.
Biochemical relapse was defined as two consecutive PSA
values > 0.2 ng/ml in the case of patients treated with
radical prostatectomy, or three consecutive increases in
PSA following PSA nadir after primary External Beam
Radiotherapy (EBRT), or three successive values demon-
strating therapy failure in the case of castration-resistant
PCa (CRPC) [4]. To exclude local relapse, all patients
underwent endorectal Magnetic Resonance Imaging
(MRI). The median time from PCa diagnosis to study
enrolment was 11.5 months (95 % CI 6.05–17.0 months).
A multidisciplinary team discussed and approved all the
cases included in this study.
After SBRT, patients were followed-up by total PSA
determination at 6-week and then every 3 months.
Patients underwent clinical examination and comorbidi-
ties were recorded after each [18F]FMCHPET/CT scan,
and every 3 months in the first 2 years of the study, and
Fig. 1 Study design
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then every 6 months. In presence of biochemical re-
currence after SBRT (two consecutive rises measured over
6 weeks), patients underwent a new [18F]FMCH-PET/CT
scan. When [18F]FMCHPET/CT showed again the
presence of oligometastatic disease, a further SBRT was
performed, while when more than three active
synchronous lesions were detected (plurimetastatic
disease), patients were treated with systemic treatment
in accordance to European Association of Urology
(EAU) Guideline (hormonal treatment or chemother-
apy), even in the presence of asymptomatic disease.
Median patients’ follow-up was 11.53 months (95 % CI
6.05–17.02 months, range 3–40). No systemic treat-
ment was delivered during study observation (patients
who developed widespread diseases were switched to
systemic therapy).
The primary endpoint of the study was the time
between the baseline [18F]FMCH-PET/CT and the
beginning of systemic therapy after the first SBRT, i.e.
systemic therapy-free survival.
Clinical examination
Medical history was recorded at enrolment, then the
patients were evaluated before the first SBRT and at
the end of the study in order to calculate the Cumu-
lative Illness Rating Scale (CIRS) of comorbidity and
their severity.
Choline PET/CT
[18F]FMCH (IASOcholine® from IASON, Graz, Austria)
was injected i.v.for the PET/CT scan (about 4 MBq/kg of
body weight). As a routine protocol, imaging started
1 min after intravenous injection, with acquisition of
dynamic PET images at one constant bed position of the
pelvic region (covering the pelvic floor and urinary blad-
der) for 6 min (1 min per frame) to overcome the effect
of urinary activity in the bladder. After this early phase,
patients rested for approximately 1 h. The whole-body
acquisition was performed thereafter in the three-
dimensional mode, using 2 min per bed position from
the base of the skull to the mid-thigh (six or seven bed
positions). Images were reconstructed with a standard
reconstruction ordered-subset expectation maximisation
iterative algorithm (two iterative steps) and reformatted
into transverse, coronal and sagittal views. Unenhanced
CT was performed for localisation and attenuation
correction (120 kV, 3.75 mm, pitch 0.984–0.5 s/rot
spacing 3.27 mm - 47 slice, AutomA™ - SmartmA™
15–100 mA Noise Index 25.03, 27-mm reconstructed
section thickness). GE Discovery ST (GE Healthcare)
was used for all scans.
PET/CT images were interpreted by two nuclear medi-
cine specialists (PAE and LM) who were aware of the
patient’s medical history and PSA values. Images were
read sequentially using advanced PET/CT review software
(Advantage for Windows, versions 4.2–7; GE Medical
Systems), which allows simultaneous scrolling through the
corresponding PET, CT and fusion images in transverse,
coronal and sagittal planes. Semi-quantitative analysis of
the abnormal radiotracer uptake was performed by using
the maximum standardised uptake value (SUVmax).
Diffusion weighted imaging (DWI), Dynamic contrast-
enhanced (DCE-MRI)
All studies included imaging of the prostate with a dedi-
cated endorectal coil (8-ch 1.5-T ID Medrad P/N
M64ERA8-HD eCoil™ or 8-ch 3.0-T ID Medrad P/N
M128ERA8-HD eCoil™) on a 3-T MR scanner, (GE Signa
Excite HD 12.0 Twin-Speed 8-channel scanner, General
Electric, Milwaukee, WI, USA) and a 1.5-T scanner (GE
Signa Excite HD 12.0 Echospeed 8-channel scanner).
Two radiologists aware of the clinical data, reviewed
independently the images (SO and LM). The post-
processing included mono- and bi-exponential ADC
map calculation for prostate imaging. For the prostate
imaging, DWI was fused with the T2 weighted images.
Each MRI scan was classified as negative, positive or
indeterminate for local relapse.
Stereotactic body radiotherapy
SBRT treatment was performed using a Varian True
Beam® platform and 6-MV photons with flattening
Table 1 Main characteristics of the patients enrolled in this study
Mean Value SE
Age 69.86 1.24
PSA ng/ dL 3.43 1.05
Gleason Score 7.34 0.17
DT_mesi (months) 10.00 6.88
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filter-free beams. RapidArc®system was used for treat-
ment planning. Axial CT images were obtained using a
Light Speed RT 16-slice simulator (GE HealthCare).
The CT image was set at 1.25-mm slices. Clinical target
volume (CTV) was defined using [18F]FMCH-PET/CT
scan imaging. Planning target volume consisted of both
bone and nodal lesions of an isotropic 3-mm expansion
of the CTV. Two different schedules of radiotherapy
were delivered: 24 Gy in a single fraction or 27 Gy in
three fractions, 2–3 sessions a week, were delivered (in
the cases when it was not possible to meet the
constraints for the single dose the dose of 27 Gy was
delivered in 3 fractions). The delivered dose was
prescribed at the periphery of the target. Before each
fraction, a cone-beam CT was performed for patient’s
set-up. Dexamethasone (4 mg) was administered 1 h
after the SBRT session in the patients treated with
24 Gy in a single fraction. Task group 101 of the
American Association of Physicists in Medicine con-
straints were used to avoid toxicity of the organs at
risk [22]. Toxicity was recorded using the Common
Terminology Criteria for Adverse Events (CTCAE)
version 4.0 .
Statistical analyses
All values are expressed as median and range, as is
customary for non-parametric data. Survival probabil-
ities without systemic therapy were estimated by the
Kaplan-Meier method. Univariate Mantel-Cox analysis
was used to examine the predictive value of covariates.
All p-values were set at 0.05. Systemic therapy-free
survival was considered the primary endpoint. Age,
CTV volume, number of treated lesions, time to
relapse, bone or nodal metastasis, the decline between
the baseline PSA pre-SBRT and the PSA value 6 weeks
after treatment (ΔPSA), CIRS severity and CIRS
comorbidity were evaluated as possible covariates.
Cases were censored at the beginning of systemic
therapy or at the last follow-up visit if no systemic
therapy was administered after SBRT. Statistical ana-
lysis was performed with SPSS v.15.0 (IBM Corp,
Somers, NY, USA).
Results
A total of 45 active lesions in 29 patients were de-
tected by [18F]FMCH-PET/CT and treated with SBRT.
[18F]FMCH-PET/CT identified 25 lesions involving
lymph nodes and 20 bone lesions. No soft tissue,
liver, adrenal or lung metastases were identified.
Twenty-three lesions were treated with single dose
radiotherapy and 22 with three fractions. Fifteen
patients were treated for the presence of nodal dis-
ease, 12 for bone lesions and two patients presented
both nodal and bone disease (Table 2). Fifteen out of
45 lesions were treated using a single arc while 30
lesions using 2 arcs. Nine patients started.
Fifteen out of the 29 patients presented biochemical
control after the first SBRT while 14 patients experi-
enced PSA recurrence. Two of these patients developed
a failure in the prostate bed after the first SBRT. They
were both treated with salvage EBRT and because the
achievement of total control PSA they were still con-
sidered oligometastatic and appropriate for this study.
After a median follow-up of 11.5 months (range 3–40
months), 15/29 patients achieved a PSA control with a
single course of SBRT, 2/29 patients with one course
plus an EBRT for a prostate bed relapse, 2/29 patients
with two courses of SBRT, one patients with three
courses and one with five (Fig. 1). systemic therapy (in
accordance with EAU Guideline) after a median time
from the baseline [18F]FMCH-PET/CT of 39.7 months
(primary endpoint, Fig. 2). All patients were alive at the
time of data analysis. Grade 2, 3 or 4 toxicity was not
recorded. Geriatric evaluation did not show any worsen-
ing during the course of the study.
The median time of the primary endpoint was
39.7 months (95 % CI 17.2–62.1 months). Cox regres-
sion analysis of the selected covariates for the primary
endpoint is reported in Table 2. CTV volume adjusted
for age resulted associated with worse outcome, how-
ever this association did not reach the statistical signifi-
cance (HR 1.197, 95 % CI 0.979–1.463, p = 0.08). Data
relate to the quality of life require a longer follow-up to
be interpreted.
Pattern of failure
Patients who experienced PSA recurrence after the
first SBRT presented the following pattern of relapse:
two patients had disease progression on the prostate
bed (treated with salvage EBRT). Four patients de-
veloped recurrence in lymph nodes and were still
suitable for further SBRT. Eight patients presented
recurrent disease classified as multi-metastatic disease and
therefore underwent systemic therapy (seven patients
ADT and one patient abiraterone acetate) (Fig. 3).
Recurrences have not been registered in the treated
lesions. Interesting, six out of 10 patients with nodal
recurrence and oligometastatic disease experienced
relapse in a node in close proximity to the previ-
ously treated lymph nodes. Patients with bone me-
tastasis, treated with SBRT, who experienced a
further bone disease relapse, did not show any
spread in the proximity of the treated lesion: they
presented new distant metastasis in other bone seg-
ments. Finally, apart one case, we observed that pa-
tients with recurrent oligometastatic disease relapsed
in the same tissue of the first diagnosed metastasis
(bone-bone, node-node).
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Discussion
A critical issue of cancer treatment, and maybe a surro-
gate outcome to be investigated, might be the postpon-
ing of disease progression and therefore the beginning of
subsequent therapy that can cause therapy-related symp-
toms [19, 20]. In recurrent PCa, PSA raise could be used
to define disease progression without evidence of active
lesions and it may be sufficient to declare the beginning
of systemic therapy, either hormonal therapy or chemo-
therapy [23, 24]. In a prospective study, we decide to
evaluate as a surrogate endpoint the delay of systemic
therapy delivery in patients with hormone naïve and
Castration resistance oligometastatic PCa.
The present paper reported the clinical outcomes of
29 patients with oligometastatic PCa treated with
[18F]FMCHPET/CT-guided SBRT within a prospective
single-institution clinical study. [18F]FMCH PET/CT was
used for both patients and target lesions selection. We
considered eligible for SBRT patients presenting high
[18F]FMCH uptake in up to three lesions at PET/CT (oligo-
metastatic disease). Even if the oligomestastatic state has
been firstly described in 1995 by Hellamn S. et al. [9], few
studies are available on the biochemical response related to
the number of active lesions revealed by [18F]FMCH-PET/
CT. On this basis, we choose to treat only patients with
three active lesions in order to improve the chances to ob-
serve a clinical response. In our series, by treating all the
active sites of disease with SBRT (delivering either 24 Gy in
a single fraction or 27 Gy in three fractions), there was a
significantly impact on patient treatment management. In
particular, we obtained disease control, as shown by PSA
levels, in 20 patients, thus avoiding the use of systemic
therapy. In the remaining nine patients, we delayed the
initiation of systemic therapy by 36 months.
Table 2 Cox regression analysis of the main covariates of the time to systemic therapy form study entry for all analysed patients
B SE Wald df Sig. HR HR 95,0 % CI
Lower Upper
Age 0,11 0,06 3,56 1,00 0,06 1,12 1,00 1,25
Delta_PSA 0,00 0,00 4,50 1,00 0,03* 1,00 1,00 1,01
Castration Resistant 0,37 0,67 0,31 1,00 0,58 1,45 0,39 5,45
Gleason Score −0,83 0,51 2,65 1,00 0,10 0,44 0,16 1,19
Metastasis (lynph node, bone, both) −0,47 0,64 0,54 1,00 0,46 0,63 0,18 2,18
Doubling time (months) 0,00 0,02 0,01 1,00 0,91 1,00 0,96 1,05
Clinical target volume (CTV) 0.16 0.01 0.27 1,00 0.1 1,18 0,97 1,42
Cirs com −1,12 0,70 2,57 1,00 0,11 0,33 0,08 1,28
Cirs sev −3,20 2,67 1,44 1,00 0,23 0,04 0,00 7,66
*Delta PSA value resulted significant in the univariate analysis while it did not after adjusting for the age
Fig. 2 Cumulative survival from study entry to Follow up (event is the primary endpoint, start of systemic therapy)
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Our results concerning the Systemic Therapy Free
Survival are in line with evidence from the literature. In
fact, in two studies with oligometaststic ADT-naïve PCa
patients treated with SBRT, the use of functional
imaging resulted in a deferral of systemic therapy by 38
and 25 months respectively, with a very high rate of
disease control. In the present analysis, we measured a
Systemic Therapy Free Survival of 39.7 months. This
time was measured since the first choline PET/CT while
in the other reported studies the ADT free survival was
calculated since the first day of SBRT. However, in these
studies PCa patients were selected by using [18F]FDG
PET/CT and [18F]FMCHPET/CT was limited to few
treated patients [12, 14].
We considered oligometastatic and therefore suitable
for local treatment, patients with less than 4 active
lesions revealed by [18F]FMCHPET/CT. PSA value was
not taken into account to prescribe a systemic therapy
for patients enrolled without the evidence of more than
three lesions. The patients enrolled into the studies con-
ducted by Berkovic et al. and Decaestecker et al. started
ADT if more than 3 active lesions were detected or in
case PSA > 50 ng/mL (only for Berkovic et al. series) [12,
14]. In our series of PCa patients, CTV volume showed
only a trend of recurrence prediction. None of the other
covariates showed any predictive significance. Such find-
ings underline the importance of a more accurate charac-
terisation of the clinical and biochemical features of the
“oligometastatic patients” that can benefit from local treat-
ment on active sites of disease.
SBRT was able to achieve disease control independ-
ently from the site of disease relapse, with the response
rates being virtually identical in cases of nodal disease
and bone metastasis. In patients with nodal disease
relapsed after SBRT and still presenting with an oligome-
tastatic pattern of disease, the failure always occurred in
nodes in close proximity to the previously treated lymph
nodes, similar to that observed by Decaester et al. [14].
We suppose that such finding is of interest because it
could be used to modify the SBRT approach in patients
with nodal disease, providing a lower fractionated radi-
ation dose on the lymph nodes of the involved chain.
Micrometastatic disease is rarely detected by imaging
modalities, thus leading to underestimation of disease
burden in the closest lymph nodes [25]. According to
the previous report [Decaester et al.], we found a con-
sistent trend in the disease relapse pattern: patients with
bone lesions tend to relapse in the bone tissues, while
lymph node metastatic patients have proximity node re-
currences. Understanding the clinical and biochemical
features of this subgroup of patients could lead to the
identification of the patients that are most likely to have
disease progression throughout the lymphatic pathway
and eventually eligible for prophylactic radiotherapy
to the nodes closer to the site of [18F]FMCHPET/CT
positive nodal recurrences.
Fig. 3 [18F]FMCH PET/CT and bone metastasis in a patient with wide spread disease
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Conclusions
The preliminary results of this study indicated that the
use of [18F]FMCHPET/CT-guided SBRT can significantly
impact on treatment management of oligometastatic
PCa patients, deferring the initiation of systemic therapy.
A better identification of patients most likely to benefit
from local therapy together with a deeper understanding
of the reason of treatment failure are warranted before
the introduction of this approach on a large scale.
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